September 26, 2014 — Clear-Cut Medical announced CE mark for its ClearSight magnetic resonance imaging (MRI) system for examination of breast tissue.
The ClearSight system is a compact MRI system intended for the intraoperative assessment of the margins of excised breast lumps taken from breast cancer patients undergoing breast conserving surgery or lumpectomy procedures. CE marking of the ClearSight system now allows for the commercialization of the system in Europe.
"This is a major milestone both for our company and for patients undergoing breast conserving surgery," said Eyal Kolka, CEO of Clear-Cut. "MRI is well-recognized as the modality of choice for breast imaging, but due to its size and cost it was practically not accessible in real-time for assisting surgical procedures. Currently as high as 30 percent of breast cancer patients undergoing lumpectomy return for a re-do operation due to 'positive margin' analyzed by a pathologist within one week or more. Now, our ClearSight system brings the power of MRI into the operating room aiming to assist the breast surgeon in improving the quality of care."
For more information: www.clrcut.com
July 02, 2026 
